ClinicalTrials.gg

Program

aglatimagene besadenovec

Also written as “AdV-tk”, “Aglatimagene besadenovec” and “Aglatimagene besadenovec + valacyclovir”.

Its studies are mostly in Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Glioblastoma · Lung Neoplasms · Ependymoma, led by Candel Therapeutics.

Furthest: phase 3, since Sep 19, 201112 company-led studies, 6 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Candel Therapeutics126 open or runningphase 3since Sep 19, 2011Dec 27, 2007Feb 2027phase 2 · NCT07332000

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 27, 2007First study: phase 2 study in GliomaFirst studyNCT00589875 · 52 enrolled · United States
  2. Mar 5, 20082 phase 1 studiesNCT00634231, NCT00638612
  3. Sep 9, 2008Phase 1 study in GliomaNCT00751270 · 15 enrolled · United States
  4. Sep 19, 2011Phase 3 study in Prostatic NeoplasmsNCT01436968 · 711 enrolled · United States, Puerto Rico
  5. Nov 19, 2013Phase 1 study in Pleural Effusion, MalignantNCT01997190 · 19 enrolled · United States
  6. Apr 14, 2015Phase 2 study in Borderline Resectable Pancreatic AdenocarcinomaNCT02446093 · 54 enrolled · United States, Mexico
  7. May 6, 2016Phase 2 study in Prostatic NeoplasmsNCT02768363 · 187 enrolled · United States, Mexico
  8. Apr 24, 2017Phase 1 study in Lung NeoplasmsNCT03131037 · 12 enrolled · United States
  9. Jul 24, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04495153 · 90 enrolled · United States
  10. Dec 17, 2025Phase 2 study in Prostatic NeoplasmsNCT07332000 · 45 planned · United States
  11. Jun 5, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07660094 · 500 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT07332000
  2. Oct 22, 2031Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07660094

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07660094Carcinoma, Non-Small-Cell Lung · United States3RecruitingOct 22, 2031500
NCT07332000Prostatic Neoplasms · United States2RecruitingFeb 202745
NCT04495153Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingDec 31, 202490
NCT03131037Lung Neoplasms · United States1CompletedDec 1, 202112
NCT02768363Prostatic Neoplasms · United States, Mexico2Active, not recruitingNov 2024187
NCT02446093Borderline Resectable Pancreatic Adenocarcinoma · United States, Mexico2Active, not recruitingDec 202554
NCT01997190Pleural Effusion, Malignant · United States1CompletedDec 201519
NCT01436968Prostatic Neoplasms · United States, Puerto Rico3Active, not recruitingAug 2024711
NCT00751270Glioma · United States1CompletedJan 201015
NCT00638612Pancreatic Neoplasms · United States1CompletedMay 201327
NCT00634231Glioma · United States1CompletedDec 20158
NCT00589875Glioma · United States2CompletedDec 201552

How it is read

Names in the registry

  • “AdV-tk”, 3 entries
  • “Aglatimagene besadenovec”, 2 entries
  • “Aglatimagene besadenovec + valacyclovir”, 1 entry
  • “aglatimagene besadenovec”, 1 entry
  • “aglatimagene besadenovec + valacyclovir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.